ACH-HYDROXYCHLOROQUINE SULFATE TABLET

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

HYDROXYCHLOROQUINE SULFATE

Saatavilla:

ACCORD HEALTHCARE INC

ATC-koodi:

P01BA02

INN (Kansainvälinen yleisnimi):

HYDROXYCHLOROQUINE

Annos:

200MG

Lääkemuoto:

TABLET

Koostumus:

HYDROXYCHLOROQUINE SULFATE 200MG

Antoreitti:

ORAL

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

ANTIMALARIALS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0107403001; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2020-10-19

Valmisteyhteenveto

_ACH-HYDROXYCHLOROQUINE SULFATE (Hydroxychloroquine sulfate tablets) _
_Page 1 of 42 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ACH-HYDROXYCHLOROQUINE SULFATE
Hydroxychloroquine Sulfate Tablets
Tablets, 200 mg, Oral
USP
ATC Code: P01BA02
Anti-Inflammatory – Antimalarial – Aminoquinolines
Accord Healthcare Inc.
Date of Initial Authorization:
3535 boul. St. Charles, Suite 704
October 19, 2020
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
January 6, 2023
Submission Control Number: 270069
_ACH-HYDROXYCHLOROQUINE SULFATE (Hydroxychloroquine sulfate tablets) _
_Page 2 of 42 _
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and Dosage
Adjustment
01/2022
7 WARNINGS AND PRECAUTIONS, Hematologic
01/2022
7 WARNINGS AND PRECAUTIONS, Musculoskeletal
01/2022
7 WARNINGS AND PRECAUTIONS, Psychiatric
01/2022
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
01/2022
7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
01/2022
7 WARNINGS AND PRECAUTIONS, Skin
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
5
4
DOSAGE AND ADMINISTRATION
........................